Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
18
12
2021
revised:
28
01
2022
accepted:
08
02
2022
pubmed:
21
3
2022
medline:
7
6
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
The SARS-CoV-2 omicron (B.1.1.529) variant, which was first identified in November, 2021, spread rapidly in many countries, with a spike protein highly diverged from previously known variants, and raised concerns that this variant might evade neutralising antibody responses. We therefore aimed to characterise the sensitivity of the omicron variant to neutralisation. For this cross-sectional study, we cloned the sequence encoding the omicron spike protein from a diagnostic sample to establish an omicron pseudotyped virus neutralisation assay. We quantified the neutralising antibody ID Neutralising antibody responses in reference sample pools sampled shortly after infection or vaccination were substantially less potent against the omicron variant than against wild-type SARS-CoV-2 (seven-fold to 42-fold reduction in ID These data highlight the extensive, but incomplete, evasion of neutralising antibody responses by the omicron variant, and suggest that boosting with licensed vaccines might be sufficient to raise neutralising antibody titres to protective levels. European Union Horizon 2020 research and innovation programme, European and Developing Countries Clinical Trials Partnership, SciLifeLab, and the Erling-Persson Foundation.
Sections du résumé
BACKGROUND
The SARS-CoV-2 omicron (B.1.1.529) variant, which was first identified in November, 2021, spread rapidly in many countries, with a spike protein highly diverged from previously known variants, and raised concerns that this variant might evade neutralising antibody responses. We therefore aimed to characterise the sensitivity of the omicron variant to neutralisation.
METHODS
For this cross-sectional study, we cloned the sequence encoding the omicron spike protein from a diagnostic sample to establish an omicron pseudotyped virus neutralisation assay. We quantified the neutralising antibody ID
FINDINGS
Neutralising antibody responses in reference sample pools sampled shortly after infection or vaccination were substantially less potent against the omicron variant than against wild-type SARS-CoV-2 (seven-fold to 42-fold reduction in ID
INTERPRETATION
These data highlight the extensive, but incomplete, evasion of neutralising antibody responses by the omicron variant, and suggest that boosting with licensed vaccines might be sufficient to raise neutralising antibody titres to protective levels.
FUNDING
European Union Horizon 2020 research and innovation programme, European and Developing Countries Clinical Trials Partnership, SciLifeLab, and the Erling-Persson Foundation.
Identifiants
pubmed: 35305699
pii: S1473-3099(22)00129-3
doi: 10.1016/S1473-3099(22)00129-3
pmc: PMC8930016
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
sotrovimab
1MTK0BPN8V
imdevimab
2Z3DQD2JHM
bamlanivimab
45I6OFJ8QH
casirivimab
J0FI6WE1QN
etesevimab
N7Q9NLF11I
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
813-820Subventions
Organisme : Medical Research Council
ID : MR/W005611/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests STR is a cofounder of and held shares in deepCDR Biologics, which has been acquired by Alloy Therapeutics. DJS, GBKH, and BM have intellectual property rights associated with antibodies that neutralise the omicron variant. All other authors declare no competing interests.
Références
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Prev Med Rep. 2021 Dec;24:101518
pubmed: 34458081
Nat Med. 2021 Nov;27(11):2025-2031
pubmed: 34526698
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Cell Rep Med. 2021 Nov 16;2(11):100450
pubmed: 34723224
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Nat Methods. 2022 Jun;19(6):679-682
pubmed: 35637307
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
N Engl J Med. 2021 Dec 2;385(23):e81
pubmed: 34587383
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Intern Med. 2021 Sep;290(3):666-676
pubmed: 34008203